ELCC 2022 Industry Satellite Symposium

Thursday 31 March 2022 18:15-19:45 CEST Forum Hall

Management of patients with oncogene-driven NSCLC: the shift towards personalized medicine



Solange Peters Centre Hospitalier Universitaire Vaudois (CHUV), (Lausanne, Switzerland)

Chair: Solange Peters



Reinhard Büttner Institute of Pathology, University Hospital of Cologne (Cologne, Germany)



Anne-Marie Baird President, Lung Cancer Europe (LuCE) (Dublin, Ireland)



Noemi Reguart Thoracic Oncology Unit, Hospital Clinic Barcelona (Barcelona, Spain)

18:15-18:18	Welcome and introduction Solange Peters (Switzerland, Chair)
18:18-18:38	Comprehensive biomarker testing: understanding the person's perspective Anne-Marie Baird (Ireland) and Solange Peters (Switzerland, Chair)
18:38-18:58	Know your options: biomarker testing as the foundation for treatment selection Reinhard Büttner (Germany)
18:58-19:13	Emerging landscape in biomarkers Noemi Reguart (Spain)
19:13-19:33	Integration: how can we bring the future forward? All, moderated by Solange Peters (Switzerland, Chair)
19:33-19:43	Q&A with the audience All, moderated by Solange Peters (Switzerland, Chair)
19:43-19:45	Meeting closure Solange Peters (Switzerland, Chair)

This program is intended to foster scientific education and exchange and will not be promotional in language, appearance, or intent. This program and/or material was developed for use outside the USA, is intended for non-US HCPs, and is to be used in accordance with local laws and regulations.



Novartis Pharma AG CH-4002 Basel Switzerland

© 2022 Novartis